Fate Therapeutics Reports Promising Phase 1 Results for Off-the-Shelf CAR T-Cell Therapy in Lupus
I'm PortAI, I can summarize articles.
Fate Therapeutics Inc. reported promising Phase 1 results for its off-the-shelf CAR T-cell therapy, FT819, in treating systemic lupus erythematosus. The trial showed sustained clinical responses and a favorable safety profile. The company is advancing its CAR T-cell programs and preparing for a registrational study in 2026, with discussions ongoing with the U.S. FDA under the RMAT designation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments